These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23053185)

  • 41. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.
    Burmeister T; Reinhardt R
    Leuk Res; 2008 Apr; 32(4):579-85. PubMed ID: 17928051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy.
    Quintás-Cardama A; Kantarjian H; Abruzzo LV; Cortes J
    Leukemia; 2007 Nov; 21(11):2394-6. PubMed ID: 17690707
    [No Abstract]   [Full Text] [Related]  

  • 43. Heparin-mediated inhibition of PCR in the accelerated phase of chronic myeloid leukaemia characterised by abundant basophilia.
    Satoh Y; Masuda A; Jona M; Nannya Y; Yokota H; Kurokawa M; Yatomi Y
    Eur J Haematol; 2014; 92(5):456-7. PubMed ID: 24373003
    [No Abstract]   [Full Text] [Related]  

  • 44. Concurrence of e1a2 and e19a2 BCR-ABL1 Fusion Transcripts in a Typical Case of Chronic Myeloid Leukemia.
    Lee J; Kim DS; Lee HS; Choi SI; Cho YG
    Ann Lab Med; 2017 Jan; 37(1):74-76. PubMed ID: 27834071
    [No Abstract]   [Full Text] [Related]  

  • 45. A Novel e8a2BCR-ABL1 Fusion Transcript without Insertion Sequence in a Patient with Chronic Myeloid Leukemia.
    Jin C; Zhu X; Xiao M; Liu S; Liu X; Liu J; Xu X; Yi S; Meng L
    Ann Lab Med; 2018 Mar; 38(2):169-171. PubMed ID: 29214763
    [No Abstract]   [Full Text] [Related]  

  • 46. Optimizing fusion transcript monitoring in CML.
    Hertzberg M; McDonald D
    Blood; 2007 Mar; 109(5):2263; author reply 2263-4. PubMed ID: 17312000
    [No Abstract]   [Full Text] [Related]  

  • 47. CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene.
    Diamond JM; de Almeida AM; Belo HJ; da Costa MP; Cabeçadas JM; Abecasis MM
    Ann Hematol; 2016 Dec; 95(12):2101-2104. PubMed ID: 27699446
    [No Abstract]   [Full Text] [Related]  

  • 48. Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.
    Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
    Leuk Lymphoma; 2014 Oct; 55(10):2398-401. PubMed ID: 24428200
    [No Abstract]   [Full Text] [Related]  

  • 49. Myeloid/natural killer cell precursor acute leukaemia with minor bcr/abl mRNA transcript.
    Ikewaki J; Otsuka E; Satou J; Miya F; Nakayama T; Kikuchi H; Kashima K; Nasu M
    Br J Haematol; 2002 Aug; 118(2):684-5. PubMed ID: 12139765
    [No Abstract]   [Full Text] [Related]  

  • 50. Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?
    Langabeer SE
    Med Oncol; 2013 Jun; 30(2):508. PubMed ID: 23430446
    [No Abstract]   [Full Text] [Related]  

  • 51. Harmonization of quantitative BCR-ABL measurements using the secondary reference material anchored to the WHO primary standards.
    Yamada H; Tabe Y; Watanabe K; Morishita S; Yuri M; Yokoo M; Horii T; Shimizu N; Kimura S; Ohsaka A
    Int J Lab Hematol; 2015 Apr; 37(2):e29-33. PubMed ID: 25041536
    [No Abstract]   [Full Text] [Related]  

  • 52. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
    Faderl S; Talpaz M; Kantarjian HM; Estrov Z
    Blood; 1999 May; 93(9):2755-9. PubMed ID: 10216068
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluation of two CE-IVD tests for
    Folta A; Jurcek T; Kubesova B; Zackova D; Semerad L; Mayer J; Jeziskova I
    Leuk Lymphoma; 2021 May; 62(5):1239-1242. PubMed ID: 33356699
    [No Abstract]   [Full Text] [Related]  

  • 54. Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia?
    Langabeer SE; Bhreathnach Ú; Cahill MR; Elhassadi E; Ní Loingsigh S; Conneally E; Enright H
    Blood Cells Mol Dis; 2021 Mar; 87():102521. PubMed ID: 33254033
    [No Abstract]   [Full Text] [Related]  

  • 55. Clonal dominance and clonal evolution in a patient with a "chronic myeloid neoplasm": a challenge in management.
    Burgstaller S; Webersinke G; Thaler J
    Leuk Lymphoma; 2015 Jan; 56(1):239-41. PubMed ID: 24766465
    [No Abstract]   [Full Text] [Related]  

  • 56. Residual bcr/abl transcripts in chronic myeloid leukaemia.
    Gabert J; Thuret I; Carcassonne Y; Maraninchi D; Mannoni P
    Lancet; 1990 Feb; 335(8686):417-8. PubMed ID: 1968151
    [No Abstract]   [Full Text] [Related]  

  • 57. Experiences with the determination of chimaera bcr-abl messages in bone marrow and peripheral blood samples in chronic myeloid leukaemia.
    Páldi-Harris P; Földi J
    Br J Haematol; 1995 Mar; 89(3):684-5. PubMed ID: 7734383
    [No Abstract]   [Full Text] [Related]  

  • 58. Chronic myeloid leukaemia: a therapeutic challenge.
    Mughal TI; Goldman JM
    Ann Oncol; 1995 Sep; 6(7):637-44. PubMed ID: 8664183
    [No Abstract]   [Full Text] [Related]  

  • 59. Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia.
    Boklan JL; Walsh AM; de la Maza MC; Su LL; Nizzi FA; Schafernak KT
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):456-457. PubMed ID: 29668550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis.
    Li Y; Shao H; Fu B
    Ann Hematol; 2019 May; 98(5):1319-1321. PubMed ID: 30377763
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.